MedTrace Logo

A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.

NCT01287338 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 143

Last updated 2013-09-17

No results posted yet for this study

Summary

The purpose of this study is to test if olopatadine punctal plugs can reduce the symptoms (itching) of allergic conjunctivitis to ragweed in an Environmental Exposure Chamber model.

Conditions

  • Seasonal Allergic Conjunctivitis to Ragweed

Interventions

DRUG

Olopatadine

low dose

DRUG

Olopatadine

high dose

Sponsors & Collaborators

  • Mati Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Dipak Panigrahi, MD · QLT Inc.

  • Deepen Patel, MD · Cetero Research, San Antonio

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01287338 on ClinicalTrials.gov